Which country developed and produced Pirtobrutinib?

Pirtobrutinib is a new generation Bruton's tyrosine kinase (BTK) inhibitor developed by the American biopharmaceutical company Rockefeller Medicine (Loxo Oncology). Loxo Oncology Focuses on the field of targeted tumor treatment and has developed a number of precision targeted drugs. In 2019, Loxo Oncology was acquired by the American pharmaceutical giant Eli Lilly (Eli Lilly). Subsequently, the R&D and commercialization of pitobrutinib was led by Eli Lilly, reflecting the United States’ leading position in targeted therapy drug innovation.

As a non-covalent, reversible BTK inhibitor, pitobrutinib is different from the first-generation covalent BTK inhibitors (such as ibrutinib) and has strong inhibitory activity against drug-resistant mutations such as C481 mutations. This drug is specially designed to overcome the resistance problem of existing BTK inhibitors. It is a new generation representative work in the field of precision tumor treatment in the United States. Its innovative mechanism and excellent drug resistance breakthrough solution have quickly gained global attention.

Pitobrutinib is mainly undergoing clinical trials in the United States, and was approved by the U.S. FDA in January 2023 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This approval makes the United States the first country in the world to approve the drug for marketing, marking that the entire process of pitobrutinib from laboratory development to clinical application has been completed in the United States. Subsequently, the drug also advanced registration applications in markets such as Europe and Japan.

Currently, the original drug of Pitobrutinib is produced and supplied globally by Eli Lilly and Company of the United States, with production bases located in the United States and other designated overseas factories. In the context that the Chinese and Asian markets have not yet been officially approved for marketing, some patients may obtain the US original drug or the Laotian generic version through overseas channels. Overall, Pitobrutinib is a standard American original drug and represents the continued innovation capabilities of American biopharmaceutical companies in the field of anti-tumor drugs.

Reference materials:https://www.drugs.com/